Figure 4 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome

Le résumé fourni par la source

B2M-mutated tumors frequently harbor somatic MMR or genomic stability mutations. A, Pie chart showing the distribution of B2M mutations occurring alone or in combination with MMR (MSH3 and MSH6) or genomic stability (POLE and POLD1) mutations. B, Sunburst charts illustrating the hierarchical distribution of tumors within each group, stratified by B2M mutation status (mutant or wild-type) and the presence or absence of at least one MMR or genomic stability mutation. C, Mosaic plot showing the distribution of IHC results (Het, heterogeneous) stratified by B2M mutation status. D, Lollipop plot of B2M mutations in samples stratified by IHC status. The plot highlights the distribution and types of somatic mutations along the B2M protein in B2M-negative and B2M-positive cases. E, Box plot showing the allele frequency of B2M mutations grouped by B2M IHC. F, Pie chart showing the distribution of tumor stages in B2M-negative colorectal cancer and urothelial cancer. Early stage was defined as stage I for colorectal cancer and non-MI for urothelial cancer, whereas advanced stage was defined as stage II–III for colorectal cancer and MI for urothelial cancer. G, Pie donut chart illustrating the distribution of B2M IHC status (inner ring) and corresponding germline mutations (outer ring). CRC, colorectal cancer; UC, urothelial cancer; WT, wild type.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.